Gilead Sciences Inc. has divulged bridged tricyclic carbamoylpyridone prodrugs acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infection.
Integrase strand transfer inhibitors (INSTI) under a once-daily oral schedule are the standard-of-care treatment for HIV. Longer-acting oral and injectable formulations to facilitate adherence to treatment regimens are needed.
Exavir Therapeutics Inc. has received a US$3 million award from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health, to support the development of XVIR-110.
Medshine Discovery Inc. has synthesized macrocyclic compounds acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infections.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Senhui Pharmaceutical Co. Ltd. have identified pyridine compounds acting as HIV integrase inhibitors reported to be useful for the treatment of HIV infections.
